靶向抑制有氧酵解联合免疫治疗在肾细胞癌中的研究进展

Progress in targeted inhibition of aerobic glycolysis combined with immunotherapy for renal cell carcinoma

肿瘤有氧酵解是肿瘤代谢重编程的主要特征之一,这种异常的糖酵解代谢途径为肿瘤生长和增殖提供生物能量和生物原材料。肿瘤细胞不仅通过有氧酵解途径为自身提供生物原材料和能量,还通过免疫微环境逃脱免疫监视,发生免疫逃逸,从而抵抗肿瘤免疫治疗,促进肿瘤的发生和发展。本文以肾细胞癌的发病机制为背景,阐述其有氧酵解代谢的特征、糖酵解代谢对肿瘤免疫微环境的影响、糖酵解代谢抑制剂对肾细胞癌免疫微环境的影响、糖酵解代谢抑制剂联合免疫检查点抑制剂治疗肾细胞癌的前景与展望。

Tumor aerobic glycolysis is one of the main features of tumor metabolic reprogramming.This abnormal glycolytic metabolism provides bioenergy and biomaterials for tumor growth and proliferation.It is worth noting that aerobic glycolysis will not only provide biological materials and energy for tumor cells,but also help tumor cells to escape immune surveillance through regulation of immune microenvironment,thereby resisting tumor immunotherapy and promoting tumor progression.Based on the pathogenesis of renal cell carcinoma,this paper describes the characteristics of aerobic glycolysis,the effect of glycolytic metabolism on the immune microenvironment of renal cell carcinoma,the effect of glycolysis inhibitors on the immune microenvironment of renal cell carcinoma,and the prospect of glycolysis inhibitors combined with immune checkpoint inhibitors in the treatment of renal cell carcinoma.